These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 28697343)
1. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Small EJ Cancer Cell; 2017 Jul; 32(1):6-8. PubMed ID: 28697343 [TBL] [Abstract][Full Text] [Related]
3. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Boissier E; Loriot Y; Vignot S; Massard C Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632 [TBL] [Abstract][Full Text] [Related]
4. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
5. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone. Jones RJ Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852 [No Abstract] [Full Text] [Related]
6. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy. Isaacsson Velho P; Eisenberger MA Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851 [No Abstract] [Full Text] [Related]
7. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer]. Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753 [TBL] [Abstract][Full Text] [Related]
8. Agents that target androgen synthesis in castration-resistant prostate cancer. Ferraldeschi R; de Bono J Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755 [TBL] [Abstract][Full Text] [Related]
9. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
10. [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway]. Audenet F; Murez T; Ripert T; Villers A; Neuzillet Y Prog Urol; 2013 Oct; 23 Suppl 1():S9-15. PubMed ID: 24314739 [TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. Nandha R J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354 [TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Bedoya DJ; Mitsiades N Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426 [No Abstract] [Full Text] [Related]
13. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885 [TBL] [Abstract][Full Text] [Related]
14. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. Bird IM; Abbott DH J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Han CS; Patel R; Kim IY Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials. Bjartell A Eur Urol; 2011 Nov; 60(5):905-7. PubMed ID: 21871707 [No Abstract] [Full Text] [Related]
17. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer]. Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735 [TBL] [Abstract][Full Text] [Related]
18. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer. Beardo-Villar P; Ledo-Cepero MJ; Gavira-Moreno R; Soto-Delgado M; Soto-Villalba J; Alvarez-Ossorio JL; Juárez-Soto A Actas Urol Esp; 2014 Jun; 38(5):339-45. PubMed ID: 24480574 [TBL] [Abstract][Full Text] [Related]
19. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606 [TBL] [Abstract][Full Text] [Related]
20. [A Case of Fulminant Hepatitis after Administration of Abiraterone Acetate]. Yumiba S; Komori K; Iwanishi T; Koida Y; Kobayashi M; Ono Y Hinyokika Kiyo; 2017 Nov; 63(11):479-482. PubMed ID: 29232800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]